

## **Flamma celebrates Grand Opening of \$20M facility in China featuring cGMP workshop and R&D center**

Dalian, China – June 19, 2017 – Flamma SpA (“Flamma”), a preeminent Contract Manufacturing Organization (CMO) that develops, manufactures, and commercializes small molecule active pharmaceutical ingredients (APIs) for the pharmaceutical industry, recently celebrated the Grand Opening of its new cGMP workshop and R&D Center in Dalian, China on June 19<sup>th</sup>. Joining the Flamma team were customers from Europe, North America, and Asia.

Dr. Gian Paolo Negrisoli, President and CEO of Flamma noted, “Flamma has been listening to its customers and their need to have a trusted supplier in China. Flamma is unique in our industry having the ability to provide customers manufacturing of APIs, RSMs, and advanced intermediates not only in Europe but also in China being led by one management team.”

This investment of \$20M brings the total capacity of Flamma’s Chinese operations in Dalian to 200 m<sup>3</sup> and brings the R&D group to the same campus for increased efficiency and productivity for their customers.

“This new cGMP workshop at Flamma Honkai will allow Flamma to expand its offerings to our customers”, notes Negrisoli, “We can also sell into the Chinese marketplace with our line of generics like minoxidil and others.”

Flamma continues to reinvest in itself for the future. By 2018, Flamma intends to spend \$5M to expand its R&D capabilities with the addition of a new R&D building at its Chignolo d’Isola headquarters. By 2020, Flamma has plans to increase its production capacity by 40% with the addition of another cGMP workshop at its Chignolo d’Isola headquarters.

“In the time that I have been at Flamma, we have increased our headcount by 4X and our sales by 6X. This is not coincidental. This is due to the quality team that Gian Paolo has put together and his leadership,” said Kenneth Drew, Ph.D., Sr. Director of North America Sales and Business Development. “While the CMO industry appears to be consolidating with mega-mergers, we feel that being a family owned, privately held and managed company has significant value to our customers. Having a long term vision is what helps to differentiate Flamma from other CMOs.”

Flamma will be present at numerous upcoming industry events to discuss its plans. These events include CPhI Worldwide in Frankfurt in October as well as ChemOutsourcing (September in New Jersey) and Outsourced Pharma (November in the SF Bay Area).

Contact Flamma

Kenneth Drew, Ph.D., Director, US Sales and Business Development

1-617-515-0975

[ken.drew@flammagroup.com](mailto:ken.drew@flammagroup.com)

**About Flamma:**

FLAMMA is a 100% family owned & run, privately held specialty Contract Manufacturer (CMO) based in Bergamo (near Milan), Italy founded in 1950. Flamma is a preeminent cGMP manufacturer of APIs including high value functional amino acids and chiral materials.

FLAMMA has 3 manufacturing facilities (each with their own R&D departments), 450 employees, and 450 m<sup>3</sup> of capacity giving FLAMMA flexibility to serve customers. Both Italian locations are cGMP & regularly inspected by the FDA & AIFA. Flamma leverages their self-owned, self-managed cGMP facilities in China to deliver results. Flamma offers cost-effective services to customers looking for a trusted partner in Europe and China.

FLAMMA - Where It Matters Most

For more information, please visit [www.flammagroup.com](http://www.flammagroup.com)